Dihydropyrimidine dehydrogenase activity and messenger RNA level may be related to the antitumor effect of 5-fluorouracil on human tumor xenografts in nude mice

Clinical Cancer Research

Volumn 5, Issue 4, 1999, Pages 883-889

  Ishikawa, Yoichiro ^a   Kubota, Tetsuro ^a   Otani, Yoshihide ^a   Watanabe, Masahiko ^a   Teramoto, Tatsuo ^a   Kumai, Koichiro ^a   Kitajima, Masaki ^a   Takechi, Teiji ^b   Okabe, Hiroyuki ^b   Fukushima, Masakazu ^b  

^a KEIO UNIVERSITY   (Japan)

^b TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; MESSENGER RNA; THYMIDYLATE SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; COLON CARCINOMA; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MESSENGER RNA SYNTHESIS; MOUSE; NONHUMAN; PANCREAS CARCINOMA; PREDICTION; PRIORITY JOURNAL; STOMACH CARCINOMA; TRANSCRIPTION REGULATION; TUMOR XENOGRAFT;

ANIMALS; DIHYDROURACIL DEHYDROGENASE (NADP); DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; OXIDOREDUCTASES; RNA, MESSENGER; THYMIDYLATE SYNTHASE; TUMOR CELLS, CULTURED;

EID: 0032945491     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Macdonald, J. S., and Gohmann, J. J. Chemotherapy of advanced gastric Cancer: present status, future prospects. Semin. Oncol., 15 (Suppl. 4): 42-49, 1988.
2. Hafstrom, L., Rudenstam, C-M., Domellof, L., and the Swedish Gastro-Intestinal Tumour Adjuvant Therapy Group. A randomized trial of oral 5-fluorouracil versus placebo as adjuvant therapy in colorectal cancer Dukes' B and C: results after 5 years observation time. Br. J. Surg., 72: 138-141, 1985.
3. Langenback, R. J., Danenberg, P. V., and Heidelberger, C. Thymidylate synthetase: mechanism of inhibition by 5-fluoro-2′-deoxyuridylate. Biochem. Biophys. Res Commun., 48: 1565-1571, 1972.
4. Matsuoka, H., Ueo, H., Sugimachi, K., and Akiyoshi, T. Preliminary evidence that incorporation of 5-fluorouracil into RNA correlates with antitumor response. Cancer Invest., 10: 265-269, 1992.
5. Peters, G. J., van der Wilt, C. L., van Groeningen, C. J., Smid, K., Meijer, S., and Pinedo, H. M. Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil. J. Clin. Oncol., 12: 2035-2042, 1994.
6. Johnston, P. G., Fisher, E. R., Rockette, H. E., Fisher, B., Wolmark, N., Drake, J. C., Chabner, B. A., and Allegra, C. J. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J. Clin. Oncol., 12: 2640-2647, 1994.
7. Johnston, P. G., Lenz, H-J., Leichman, C. G., Danenberg, K. D., Allegra, C. J., Danenberg, P. V., and Leichman, L. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res., 55: 1407-1412, 1995.
8. Lenz, H-J., Leichman, C. G., Danenberg, K. D., Danenberg, P. V., Groshen, S., Cohen, H., Laine, L., Crookes, P., Silberman, H., Baranda, J., Garcia, Y., Li, J., and Leichman, L. Thymidylate synthase mRNA level in adenocarcinoma of the stomach. J. Clin. Oncol., 14: 176-182, 1995.
9. Leichman, C. G., Lenz, H-J., Leichman, L., Danenberg, K., Baranda, J., Groshen, S., Boswell, W., Metzger, R., Tan, M., and Danenberg, P. V. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J. Clin. Oncol., 75: 3223-3229, 1997.
10. Beck, A., Etienne, M. C., Cheradame, S., Fischel, J. L., Formento, P., Renee, N., and Milano, G. A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur. J. Cancer, 30A: 1517-1522, 1994.
11. Etienne, M. C., Cheradame, S., Fischel, J. L., Formento, P., Dassonville, O., Renee, N., Schneider, M., Thyss, A., Demard, F., and Milano, G. Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J. Clin. Oncol., 13: 1663-1670, 1995.
12. Jiang, W., Lu, Z., He, Y., and Diasio, R. B. Dihydropyrimidine dehydrogenase activity in hepatocellular carcinoma: implication in 5-fluorouracil-based chemotherapy. Clin. Cancer Res., 3: 395-399, 1997.
13. McLeod, H. L., Sludden, J., Murray, G. I., Keenan, R. A., Davidson, A. I., Park, K., Koruth, M, and Cassidy, J. Characterization of dihydropyrimidine dehydrogenase in human colorectal tumours. Br. J. Cancer, 77: 461-465, 1988.
14. Milano, G., Fischel, J. L., Spector, T., Etienne, M. C., and Formento, P. Enhancement of fluorouracil cytotoxicity by inhibiting dihydropyrimidine dehydrogenase activity with 5-etynyluracil cytotoxicity by inhibiting dihydropyrimidine dehydrogenase activity with 5-ethynyl-uracil. Proc. Am. Assoc. Cancer Res., 36: 292, 1995.
15. Takechi, T., Uchida, J., Fujioka, A., and Fukushima, M. Enhancing 5-fluorouracil cytotoxicity by inhibiting dihydropyrimidine dehydrogenase activity with uracil in human tumor cells. Int. J. Oncol., 11: 1041-1044, 1997.
16. Takechi, T., Uchida, J., Takeda, S., and Fukushima, M. Enhancement of 5-fluorouracil cytotoxicity by dihydropyrimidine dehydrogenase inhibitor, 5-chloro-2,4-dihydroxypyrimidine. Proc. Jpn. Cancer Assoc., 87 (Suppl.): 639, 1996.
17. Kubota, T., Kawamura, E., Kurihara, H., Ishibiki, K., and Abe, O. Clinical study of clonogenic assay-with reference to adjuvant cancer chemotherapy after operation. J. Jpn. Surg. Soc., 87: 154-161, 1986.
18. Suto, A., Kubota, T., Shimoyama, Y., Ishibiki, K., and Abe, O. MTT assay with reference to the clinical effect of chemotherapy. J. Surg. Oncol., 42: 28-32, 1989.
19. Saikawa, Y., Kubota, T., Furukawa, T., Suto, A., Watanabe, M., Kumai, K., Ishibiki, K., and Kitajima, M. Single-cell suspension assay with an MTT end point is useful for evaluating the optimal adjuvant chemotherapy for advanced gastric cancer. Jpn. J. Cancer Res., 85: 762-765, 1994.
20. Furukawa, T., Kubota, T., and Hoffman, R. M. Clinical application of the histoculture drug response assay. Clin. Cancer Res., 1: 305-311, 1995.
21. Kubota, T., Sasano, N., Abe, O., Nakao, I., Kawamura, E., Saito, T., Endo, M., Kimura, K., Demura, H., Sasano, H., Nagura, H., Ogawa, N., Hoffman, R. M., and the Chemosensitivity Study Group for the Histoculture Drug-Response Assay. Potential of the histoculture drug-response assay to contribute to cancer patient survival. Clin. Cancer Res., 1: 1537-1543, 1995.
22. Nagai, S., Yamauchi, M., Andoh, T., Nishizawa, M., Satta, T., Kodera, Y., Kondou, K., Akiyama, S., Ito, K., and Takagi, H. Establishment and characterization of human gastric and colonic xenograft lines resistant to CPT-11 (a new derivative of camptothecin). J. Surg. Oncol., 59: 116-124, 1995.
23. Fujita, F., Fujita, M., Taguchi, T., Shimozuma, K., Sakamoto, Y., Kimoto, Y., and Hirai, T. Multifactorial analysis of parameters influencing Chemosensitivity of human cancer xenografts in nude mice. Int. J. Cancer., 43: 637-644, 1989.
24. Yamada, Y., Nakatani, K., Watanabe, A., Okumura, T., Yano, T., Yamada, Y., and Nakano, H. Expression of malignant potential of human colon cancer in nude mice: preliminary report. J. Jpn. Surg. Soc., 91: 787, 1990.
25. Nomura, T., Sakurai, Y., and Inada, M. The Nude Mouse and Anticancer Drug Evaluation, pp. 84-87. Tokyo: Japanese Journal of Cancer and Chemotherapy Publishers Inc., 1996.
26. Giovanella B. C., Stehlin J. S., and Williams, L. J., Jr. Heterotransplantation of human malignant tumors in "nude" thymusless mice. II. Malignant tumors induced by injection of cell cultures derived from human solid tumors. J. Natl. Cancer Inst. (Bethesda), 52: 921-930, 1974.
27. Kubota, T., Nakada, M., Tsuyuki, K., Inada, T., Asanuma, F., Ishibiki, K., and Abe, O. Cell kinetics and Chemosensitivity of human carcinomas serially transplanted into nude mice. Jpn. J. Cancer Res., 77: 502-507, 1986.
28. Geran, R. I., Greenberg, N. H., Macdonald, M. M., Schumacher, A. H., and Abbott, B. J. Protocols for screening chemical agents and natural products against animal tumors and other biological systems. Cancer Chemother. Rep., 3: 51-61, 1972.
29. Kubota, T., Ishibiki, K., and Abe, O. The clinical usefulness of human xenografts in nude mice. Prog. Clin. Biol. Res., 276: 213-225, 1988.
30. Spears, C. P., Shahinian, A. H., Moran, R. G., Heidelberger, C., and Corbett, T. H. In vivo kinetics of thymidylate synthetase inhibition in 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas. Cancer Res., 42: 450-456, 1982.
31. Ikenaka, K., Shirasaka, T., Kitano, S., and Fujii, S. Effect of uracil on metabolism of 5-fluorouracil in vitro. Gann, 70: 353-359, 1979.
32. Takechi, T., Okabe, H., Fujioka, A., and Fukushima, M. Relationship between protein levels and gene expression of dihydropyrimidine dehydrogenase in human tumor cells during growth in culture and in nude mice. Jpn. J. Cancer Res., 89: 1144-1153, 1999.
33. Takeishi, K., Kaneda, S., Ayusawa, D., Shimizu, K., Gotoh, O., and Seno, T. Nucleotide sequence of a functional cDNA for human thymidylate synthase. Nucleic Acid Res., 13: 2035-2045, 1985.
34. Yokota, H., Fernandez-Salguero, P., Furuya, H., Lin, K., McBride, O. W., Podschun, B., Schnackerz, K. D., and Gonzalez, F. J. cDNA cloning and chromosome mapping of human dihydropyrimidine dehydrogenase, an enzyme associated with 5-fluorouracil toxicity and congenital thymine uraciluria. J. Biol. Chem., 269: 23192-23196, 1994.
35. Tokunaga, K., Nakamura, Y., Sakata, K., Fujimori, K., Ohkubo, M., Sawada, K., and Sakiyama, S. Enhanced expression of a glyceraldehyde-3-phosphate dehydrogenase gene in human lung cancers. Cancer Res., 47: 5616-5619, 1987.
36. Perryman, S. M., Rossana, C., Deng, T., Vanin, E. F., and Johnson, L. F. Sequence of a cDNA for mouse thymidylate synthase reveals striking similarity with the prokaryotic enzyme. Mol. Biol. Evol., 3: 313-321, 1986.
37. Sabath, D. E., Broome, H. E., and Prystowsky, M. B. Glyceraldehyde-3-phosphate dehydrogenase mRNA is a major interleukin 2-induced transcript in a cloned T-helper lymphocyte. Gene, 91: 185-191, 1990.
38. Diasio, R. B., Danenberg, K., Johnson, M., and Danenberg, P. Quantitation of dihydropyrimidine dehydrogenase expression in tumor specimens of patients treated with 5-fluorouracil using a quantitative polymerase chain reaction assay. Proc. Am. Assoc. Cancer Res., 39: 188, 1998.
39. Inada, T., Ichikawa, A., Kubota, T., Ogata, Y., Moossa, A. R., and Hoffman, R. M. 5-FU-induced apoptosis correlates with efficacy against human gastric and colon cancer xenografts in nude mice. Anticancer Res., 17: 1965-1972, 1997.
40. Lenz, H-J., Hayashi, K., Salonga, D., Danenberg, K. D., Danenberg, P. V., Metzger, R., Banerjee, D., Bertino, J. R., Groshen, S., Leichman, L. P., and Leichman, C. G. p53 point mutation and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. Clin. Cancer Res., 4: 1243-1250, 1998.
41. Lenz, H-J., Danenberg, K. D., Leichman, C. G., Florentine, B., Johnston, P. G., Groshen, S., Zhou, L., Xiong, Y. P., Danenberg, P. V., and Leichman, L. P. p53 and thymidylate synthase expression in untreated stage II colon cancer: association with recurrence, survival, and site. Clin. Cancer Res., 4: 1227-1234, 1998.
42. Harris, B. E., Song, R., Soong S-J., and Diasio, R. B. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res., 50: 197-201, 1990.-